• On May 12, 2026, Alkermes announced positive topline Phase 3 REVITALYZ results showing that once‑nightly LUMRYZ improved excessive daytime sleepiness and other idiopathic hypersomnia symptoms versus placebo, supporting plans to file a supplemental New Drug Application with the FDA by the end of 2026.
• A key nuance for investors is that, under an existing settlement, Alkermes cannot market LUMRYZ for idiopathic hypersomnia before March 1, 2028, even if it secures earlier FDA approval.
• We’ll now examine how these Phase 3 data, and the delayed ability to market LUMRYZ in idiopathic hypersomnia, reshape Alkermes’ investment narrative.

Uncover the next big thing with 28 elite penny stocks that balance risk and reward.

Alkermes Investment Narrative Recap

To own Alkermes today, you need to believe its sleep and neuropsychiatry portfolio can support durable earnings, despite a high valuation and rising R&D spend. The positive Phase 3 REVITALYZ data for LUMRYZ in idiopathic hypersomnia strengthens the sleep franchise story, but the 2028 marketing restriction tempers expectations for near term revenue from this indication. In the short term, the key catalyst remains execution across existing products, while a major risk is that higher R&D outlays do not translate into successful approvals.

The recent first quarter 2026 results put the LUMRYZ news in context. Alkermes reported US$392.9 million in revenue but swung to a net loss of US$66.5 million, highlighting the earnings pressure that can come with investing in late stage trials like REVITALYZ and the orexin agonist program. For investors, the Phase 3 success arrives at a time when the company is already absorbing higher costs and facing scrutiny over whether current profitability levels are sustainable.

Yet beneath the positive trial headline, investors should also be aware of the risk that rising R&D and pricing pressure could...

Alkermes' narrative projects $2.1 billion revenue and $238.9 million earnings by 2029.

Uncover how Alkermes' forecasts yield a $44.24 fair value, a 14% upside to its current price.

Exploring Other Perspectives

While the REVITALYZ win supports the sleep thesis, the lowest analysts were assuming Alkermes revenue could fall to about US$1.3 billion and earnings to roughly US$184 million, reminding you that some expect orexin class risks and pricing pressure to weigh far more heavily than the consensus view.

Explore 5 other fair value estimates on Alkermes - why the stock might be worth over 2x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Alkermes research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Alkermes research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alkermes' overall financial health at a glance.

Contemplating Other Strategies?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• We've uncovered the 14 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Rare earth metals are the new gold rush. Find out which 33 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.